Nitazene Contamination in Illicit Supply Prompts Updated FTS Guidance

Harm reduction organizations across North America and Europe have issued updated guidance following a surge in nitazene-class synthetic opioid detection in the illicit drug supply. Nitazenes — a class of highly potent synthetic opioids including isotonitazene and metonitazene — are concerning because they do not reliably trigger standard fentanyl test strip results, creating a false sense of safety for users relying solely on FTS testing.

Public health agencies in Ontario, British Columbia, the UK, and Germany have all reported confirmed nitazene detections in substances sold as heroin, counterfeit oxycodone, and other opioids. Potency varies significantly between nitazene variants, and the effective dose range for some compounds is narrower than fentanyl.

Updated harm reduction guidance recommends: treating all FTS-negative opioid samples as potentially containing undetectable synthetic opioids; reducing initial doses to a fraction of the normal amount regardless of test results; ensuring naloxone availability (multiple doses may be required); and using the Never Use Alone hotline (1-800-484-3731) for all opioid use sessions.